We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ashland Q3 Earnings and Sales Lag Estimates, Guidance Narrowed
Read MoreHide Full Article
Key Takeaways
ASH reported Q3 loss of $742M, or $16.21 per share, with adjusted earnings of $1.04 missing estimates.
Sales fell 14.9% YoY to $463M, hurt by divestitures, lower volumes and reduced pricing.
Ashland narrowed FY25 sales outlook to $1.825B-$1.85B and EBITDA guidance to $400M-$410M.
Ashland Global Holdings Inc. (ASH - Free Report) recorded a loss of $742 million or $16.21 per share in third-quarter fiscal 2025 (ended June 30) compared with a profit of $6 million or 12 cents in the prior-year quarter.
Barring one-time items, adjusted earnings were $1.04 per share, down from the year-ago quarter’s figure of $1.49. The bottom line missed the Zacks Consensus Estimate of $1.15.
Sales were down 14.9% year over year to $463 million. The top line missed the Zacks Consensus Estimate of $468.4 million. Sales for the fiscal third quarter were adversely impacted by the portfolio optimization actions involving curtailing or divesting certain lower-margin products, lower volumes in Specialty Additives and Personal Care, and reduced pricing in Life Sciences and Intermediates.
Life Sciences:Sales in the segment were down 17% year over year to $162 million in the reported quarter. The Zacks Consensus Estimate for the same was $170 million. The decline was primarily caused by the divestiture of the Neutraceuticals division and the exit of the low-margin nutrition offerings.
Personal Care:Sales in the division declined 16% year over year to $147 million. The metric met the Zacks Consensus Estimate. The decrease was mostly due to portfolio optimization, mainly attributed to the divestiture of the Avoca business line.
Specialty Additives:Sales in the segment fell 13% year over year to $131 million but beat the Zacks Consensus Estimate of $124 million. The decline was mostly due to the exit from the low-margin construction business to optimize the portfolio.
Intermediates: Sales in the segment went down 8% year over year to $33 million. The figure also missed the consensus estimate of $34.8 million. The overall sales decreased, mostly due to lower prices.
ASH’s Financials
Cash and cash equivalents were $207 million at the end of the quarter, up around 23.2% sequentially. Long-term debt was $1,382 million, up roughly 3.4% over the same time frame.
ASH’s Outlook
For the full fiscal year, Ashland now expects sales to be in the range of $1.825-$1.85 billion and adjusted EBITDA to be $400-$410 million, narrowing from the previous estimate of $1.825-$1.9 billion and $400-$420 million, respectively.
ASH’s Price Performance
Shares of Ashland have lost 42.5% in the past year compared with a 1.3% decline in the industry.
Image Source: Zacks Investment Research
ASH’s Zacks Rank & Key Picks
ASH currently carries a Zacks Rank #5 (Strong Sell).
Better-ranked stocks worth a look in the basic materials space include Royal Gold, Inc. (RGLD - Free Report) , Lithium Americas Corp. (LAC - Free Report) and MAG SilverCorp. (MAG - Free Report) .
Royal Gold is slated to report second-quarter results on Aug. 6. The Zacks Consensus Estimate for earnings is pegged at $1.70 per share. RGLD’s earnings beat the Zacks Consensus Estimate in each of the last four quarters, with the average surprise being 9%. Royal Gold flaunts a Zacks Rank #1 (Strong Buy) at present. You can seethe complete list of today’s Zacks #1 Rank stocks here.
Lithium Americas is expected to report second-quarter results on Aug. 12. The Zacks Consensus Estimate for LAC’s second-quarter earnings is pegged at a loss of 4 cents per share, indicating year-over-year growth of 20%. Lithium Americas’ earnings beat the Zacks Consensus Estimate in one of the last four quarters but missed it in the rest. LAC currently carries a Zacks Rank #2 (Buy).
MAG Silver is slated to report second-quarter results on Aug. 11. The consensus estimate for MAG’s earnings is pegged at 26 cents per share. MAG carries a Zacks Rank #2 at present. MAG Silver’s earnings beat the consensus estimate in three of the last four quarters, while missing it in one, with the average surprise being 2.01%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Ashland Q3 Earnings and Sales Lag Estimates, Guidance Narrowed
Key Takeaways
Ashland Global Holdings Inc. (ASH - Free Report) recorded a loss of $742 million or $16.21 per share in third-quarter fiscal 2025 (ended June 30) compared with a profit of $6 million or 12 cents in the prior-year quarter.
Barring one-time items, adjusted earnings were $1.04 per share, down from the year-ago quarter’s figure of $1.49. The bottom line missed the Zacks Consensus Estimate of $1.15.
Sales were down 14.9% year over year to $463 million. The top line missed the Zacks Consensus Estimate of $468.4 million. Sales for the fiscal third quarter were adversely impacted by the portfolio optimization actions involving curtailing or divesting certain lower-margin products, lower volumes in Specialty Additives and Personal Care, and reduced pricing in Life Sciences and Intermediates.
Ashland Inc. Price, Consensus and EPS Surprise
Ashland Inc. price-consensus-eps-surprise-chart | Ashland Inc. Quote
ASH’s Segment Highlights
Life Sciences:Sales in the segment were down 17% year over year to $162 million in the reported quarter. The Zacks Consensus Estimate for the same was $170 million. The decline was primarily caused by the divestiture of the Neutraceuticals division and the exit of the low-margin nutrition offerings.
Personal Care:Sales in the division declined 16% year over year to $147 million. The metric met the Zacks Consensus Estimate. The decrease was mostly due to portfolio optimization, mainly attributed to the divestiture of the Avoca business line.
Specialty Additives:Sales in the segment fell 13% year over year to $131 million but beat the Zacks Consensus Estimate of $124 million. The decline was mostly due to the exit from the low-margin construction business to optimize the portfolio.
Intermediates: Sales in the segment went down 8% year over year to $33 million. The figure also missed the consensus estimate of $34.8 million. The overall sales decreased, mostly due to lower prices.
ASH’s Financials
Cash and cash equivalents were $207 million at the end of the quarter, up around 23.2% sequentially. Long-term debt was $1,382 million, up roughly 3.4% over the same time frame.
ASH’s Outlook
For the full fiscal year, Ashland now expects sales to be in the range of $1.825-$1.85 billion and adjusted EBITDA to be $400-$410 million, narrowing from the previous estimate of $1.825-$1.9 billion and $400-$420 million, respectively.
ASH’s Price Performance
Shares of Ashland have lost 42.5% in the past year compared with a 1.3% decline in the industry.
Image Source: Zacks Investment Research
ASH’s Zacks Rank & Key Picks
ASH currently carries a Zacks Rank #5 (Strong Sell).
Better-ranked stocks worth a look in the basic materials space include Royal Gold, Inc. (RGLD - Free Report) , Lithium Americas Corp. (LAC - Free Report) and MAG SilverCorp. (MAG - Free Report) .
Royal Gold is slated to report second-quarter results on Aug. 6. The Zacks Consensus Estimate for earnings is pegged at $1.70 per share. RGLD’s earnings beat the Zacks Consensus Estimate in each of the last four quarters, with the average surprise being 9%. Royal Gold flaunts a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Lithium Americas is expected to report second-quarter results on Aug. 12. The Zacks Consensus Estimate for LAC’s second-quarter earnings is pegged at a loss of 4 cents per share, indicating year-over-year growth of 20%. Lithium Americas’ earnings beat the Zacks Consensus Estimate in one of the last four quarters but missed it in the rest. LAC currently carries a Zacks Rank #2 (Buy).
MAG Silver is slated to report second-quarter results on Aug. 11. The consensus estimate for MAG’s earnings is pegged at 26 cents per share. MAG carries a Zacks Rank #2 at present. MAG Silver’s earnings beat the consensus estimate in three of the last four quarters, while missing it in one, with the average surprise being 2.01%.